Pooled Analysis of S-1 Trials in Non-Small Cell Lung Cancer According to Histological Type
. T( V" O8 e! m: R) ONOBUYUKI YAMAMOTO1, TAKEHARU YAMANAKA2, YUKITO ICHINOSE3, KAORU KUBOTA4, HIROSHI SAKAI5, AKIHIKO GEMMA6, NAGAHIRO SAIJO7, MASAHIRO FUKUOKA8 and HISANOBU NIITANI9
0 A1 B5 E9 R/ T, }- P# P+ Author Affiliations
. A% F& p1 L% Q$ o: D7 @0 J; H) K# e
1Division of Thoracic Oncology, Shizuoka Cancer Center, Shizuoka 411-8777, Japan ' ^, \4 y, P9 b3 c
2Cancer Biostatistics Laboratory, Institute for Clinical Research, National Kyushu Cancer Center, Fukuoka 811-1395, Japan ) [! a( [# A2 \0 o; p: O. K
3Department of Thoracic Oncology, National Kyushu Cancer Center, Fukuoka 811-1395, Japan ' m. a& _3 ^1 j8 k! e+ f, u
4Division of Thoracic Oncology, National Cancer Center Hospital, Tokyo 104-0045, Japan ' E9 a! M5 F/ G# X8 w5 a. ^. b2 O! J
5Division of Thoracic Oncology, Saitama Cancer Center, Saitama 362-0806, Japan W5 ~# I4 ]3 U- z+ }! J p5 D
6Division of Pulmonary Medicine, Infectious Diseases, and Oncology Department of Internal Medicine, Nippon Medical School, Tokyo 113-8603, Japan
" Q! o1 g" q7 _7Kinki University School of Medicine, Osaka 589-8511, Japan 2 {% R' P, P7 z, o" u9 w
8Izumi Municipal Hospital, Osaka 594-0071, Japan + N! h0 o! ~1 M( t+ C& B
9Tokyo Cooperative Oncology Group, Tokyo 105-0013, Japan 4 R k/ \3 [% k+ o# x
Correspondence to: Nobuyuki Yamamoto, Division of Thoracic Oncology, Shizuoka Cancer Center, 1007 Shimonagakubo, Nagaizumi-cho, Sunto-gun, Shizuoka 411-8777, Japan. Tel: +81 559895222, Fax: +81 559895783, e-mail: n.yamamoto@scchr.jp # N+ b: V9 J; s8 G8 P
AbstractBackground: The antimetabolic agent S-1 inhibits thymidylate synthase similar to pemetrexed, but through a different mechanism of action. Whether the antitumour activity of S-1 depends on histological type remains unclear. We analysed pooled data from 2 phase II clinical studies of cisplatin and S-1 in patients with previously untreated advanced non-small cell lung cancer. Patients and Methods: We comprised 110 patients with stage IIIB or IV non–small cell lung cancer. Univariate and multivariate analyses were performed to determine the effects of histological type on progression-free survival and response rates. Results: On pooled analysis of the data, according to histological type, median progression-free survival was 3.8 months in patients with squamous cell carcinoma and 4.4 months in those with non-squamous cell carcinoma. Both analyses showed that progression-free survival and response rate did not differ significantly. Conclusion: Unlike molecular targeted agents and pemetrexed, a combination of cisplatin and S-1 may be no difference in response according to histological type. ; f' \ f/ y7 t' z
% h$ E8 r9 l0 ^$ V% D3 r+ w |